General. All NMR spectra were recorded on a 400 MHz FT-NMR DRX-400 FT-NMR spectrometer or 500 MHz Bruker DRX-500 FT-NMR spectrometer. 1 H chemical shifts are reported in  values in ppm downfield with the deuterated solvent as the internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), integration, coupling constant (Hz). High resolution mass spectra were recorded on a Waters Q-TOF API-US plus Acquity system with electrospray ionization. Reversed-phase LCMS analysis was performed using an Agilent 1200 system comprising a binary pump with degasser, high-performance autosampler, thermostatted column compartment, diode-array detector (DAD) and a C18 column. Flow from the column was split to a 6130 SQ mass spectrometer and Polymer Labs ELSD. The MS detector was configured with an electrospray ionization source. Data acquisition was performed with Agilent Chemstation and Analytical Studio Reviewer software. Samples were separated on a ThermoFisher Accucore C18 column (2.6 um, 2.1 x 30 mm) at 1.5 mL/min, with column and solvent temperatures maintained at 45 C. The gradient conditions were 7% to 95% acetonitrile in water (0.1% TFA) over 1.1 minutes. Low-resolution mass spectra were acquired by scanning from 135 to 700 AMU in 0.25 seconds with a step size of 0.1 AMU and peak width of 0.03 minutes. Drying gas flow was 11 liters per minute at a temperature of 350 C and a nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, and the fragmentor voltage was 100V. Preparative purification was performed on a custom HP1100 purification system (reference 16) with collection triggered by mass detection. Solvents for extraction, washing and chromatography were HPLC grade. All reagents were purchased from Aldrich Chemical Co. and were used without purification. (3-(2-((4-acetamidophenyl) thio)acetyl)-2,5-dimethyl-1H-pyrrol-1-yl)benzoate (1), ML397. Probe compound ML397 (VU0155094) is commercially available compound and was purchased from ChemDiv and had the following characterization. LCMS: R T = 2.481 min, >99% @ 254 nm, >99% @ 215 nm; m/z [M + H] + = 437. 1 H NMR (400 MHz, CDCl3, δ ppm): 8.18 (dd; J = 6.8, 2 Hz, 2 H), 7.42 (d; J = 8.8 Hz, 2 H), 7.38 (d; J = 8.8 Hz; 2 H), 7.34-7.29 (m; 6 H), 6.33 (s; 1 H), 4.03 (s; 2H), 3.97 (s, 3 H), 2.30 (s; 3 H), 2.16 (s; 3 H), 1.99 (s; 3 H). HRMS calculated for C 24 H 24 N 2 O 4 S [M + H] + m/z: 437.1535, measured: 437.1539.
Representative procedure A:
3-chloro-4-((5-chloropyridin-2-yl)oxy)aniline (18). To a microwave vial (20 mL) was added 4amino-2-chlorophenol (1) (1.0 g, 6.97 mmol, 1.0 eq), 5-chloro-2-fluoropyridine (2) (0.7 mL, 6.97 mmol, 1.0 eq), K 2 CO 3 (1.44 g, 10.45 mmol, 1.5 eq) and DMF (10 mL). The rxn mixture was subjected to microwave irradiation at 150°C for 45 min. The rxn was added to EtOAc:water (1:1, 1000 mL) and the organic layer was separated. The water layer was re-extracted with EtOAc (3 x 50 ml) and the combined organic layers were washed with water (2 x 50 mL), brine (50 mL), dried (MgSO4), filtered and concentrated. The residue was purified on a Biotage Isolera One (Zip 80 column, 50-100% EtOAc:hexanes) to afford 3-chloro-4-((5-chloropyridin-2yl)oxy)aniline (3)(1.36g, 76% yield). LCMS: RT = 0.796 min, >98% @ 215 and 254 nM, m/z = 254.8 [M + H]+.
N-(3-chloro-4-((5-chloropyridin-2-yl)oxy)phenyl)picolinamide (24).
To a solution of 3chloro-4-((5-chloropyridin-2-yl)oxy)aniline (1.36g, 5.35 mmol, 1.0 eq) and Hunig's Base (2.05 mL, 11.78 mmol, 2.2 eq) in DMF (30 mL) at 0°C was added picolinoyl chloride hydrochloride (1.05g, 5.89 mmol, 1.1 eq). After 15 min, the ice bath was removed. After 12 h at rt, the rxn was added to EtOAc:H 2 O (1:1, 500 mL). The separated organic layer was washed with NaHCO 3 (aq) (50 mL), H 2 O (3 x 50 mL), Brine (50 mL) and dried (MgSO 4 ). The mixture was filtered and the solvent removed under vacuo. The residue was purified by recrystalization (EtOH) to afford N-(3-chloro-4-((5-chloropyridin-2-yl)oxy)phenyl)picolinamide (5) (1.17 g, 59% yield). LCMS: R T = 1.214 min, >98% @ 215 and 254 nM, m/z = 359.6 [M + H] + ; 1 H NMR (400 MHz, , d-DMSO):  10.93 (br s, 1H), 8.77 (d, J = 4.0 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 2H), 8.09 (ddd, J = 7.6, 7.6, 1.6 Hz, 1H), 7.99 (dd, J = 8.8, 2.7 Hz, 1H), 7.92 (dd, J = 8.8, 2.5 Hz, 1H), 7.71 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.20 (d, J = 8.8 Hz, 1H) ; HRMS, calc'd for C 17 H 12 N 3 O 2 Cl 2 [M + H] + , 360.0307; found 360.0304. (VU0468764, 4j) . To a solution of 2-methylthiazole-4-carboxylic acid (56 mg, 0.39 mmol, 1 eq), DIEA (0.20 mL, 1.2 mmol, 3 eq) and HATU (149 mg, 0.39 mmol, 1 eq) in DMF (2 mL) was added 3-chloro-4-((5-chloropyridin-2-yl)oxy)aniline (100 mg, 0.39 mmol, 1.0 eq) at rt. The rxn was heated to 35°C. After 48 h, the rxn was filtered and purified by Gilson HPLC (acetonitrile:water w/0.1% TFA). The fractions were collected and added to EtOAc: NaHCO3 (aq). The organic layer was washed with water, Brine and dried (MgSO4), filtered and concentrated to afford N-(3-chloro-4-((5-chloropyridin-2-yl)oxy)phenyl)-2-methylthiazole-4carboxamide (7) . In the first round of data fitting, it was assumed that there was no effect on orthosteric agonist affinity (i.e., α=1) and the E m value was shared across datasets. Data were assessed statistically using a one-way ANOVA with a Tukey's post-test to compare all columns. Revised data analysis accounting for affinity modulation (α shared) is shown in Supplemental Tables 2 and 3 and Tables 5 and 6 All p values<0.05 (a) pK A for mGlu 4 /LSP4-2022 in absence of modulator versus either mGlu 4 /LSP4-2022/VU0155094 or mGlu 4 /LSP4-2022/VU0422288 (b) pK A for mGlu 7 /glutamate in absence of modulator versus mGlu 7 /glutamate/VU0155094 and mGlu 7 /glutamate/VU0155094 versus mGlu 7 /glutamate/VU0422288 (c) pK A significantly different for mGlu 7 /L-AP4 in absence of modulator versus mGlu 7 /L-AP4/VU0422288 (d) pK A for mGlu 7 /LSP4-2022 in absence of modulator versus mGlu 7 /LSP4-2022/VU0155094 (e) pK A significantly different from each other in all conditions, mGlu 8 /L-AP4 in absence of modulator, mGlu 8 /L-AP4/VU0155094, and mGlu 8 /L-AP4/VU0422288 (f) pK A for mGlu 8 /LSP4-2022 in absence of modulator versus mGlu 8 /LSP4-2022/VU0155094 or mGlu 8 /LSP4-2022/VU0422288 # E m value constrained to the maximal level of potentiation observed for that subtype between any combination of ligands in a given experiment; the mean is reported. All p values<0.05 (a) pK A for mGlu 4 /L-AP4 in absence of modulator versus mGlu 4 /L-AP4/VU0422288 (b) pK A for mGlu 4 /LSP4-2022 in absence of modulator versus mGlu 4 /LSP4-2022/VU0422288 (c) pK A for mGlu 7 /L-AP4/VU0155094 versus mGlu 7 /L-AP4/VU0422288 (d) pK A for mGlu 8 /L-AP4 in absence of modulator versus mGlu 8 /L-AP4/VU0422288 and mGlu 8 /L-AP4/VU0155094 versus mGlu 8 /L-AP4/VU0422288 (e) pK A for mGlu 8 /LSP4-2022 in absence of modulator versus mGlu 8 /LSP4-2022/VU0422288 and mGlu 8 /LSP4-2022/VU0155094 versus mGlu 8 /LSP4-2022/VU0422288 (f) Log τ A for mGlu 4 /L-AP4 in the absence of modulator versus mGlu 4 /L-AP4/VU0422288 (g) Log τ A for mGlu 8 /L-AP4 in the absence of modulator versus mGlu 8 /L-AP4/VU0422288 (h) Log τ A for mGlu 8 /LSP4-2022 in the absence of modulator versus mGlu 8 /LSP4-2022/VU0155094 or mGlu 8 /LSP4-2022/VU0422288 Supplemental Table 3 . Summary of agonist affinity and efficacy estimates across each group III mGlu subtype. To directly fit the data represented in Figure S3 , we used Equation 2.
Representative Procedure B:

N-(3-chloro-4-((5-chloropyridin-2-yl)oxy)phenyl)-2-methylthiazole-4-carboxamide
Supplemental
The system maximum (E m ) was constrained to the maximum level of potentiation observed for any agonist/potentiator pair (all above 100% of agonist E max ) for calcium assays and to a value just above the largest agonist max value for GIRK assays. For statistical analyses, Logτ A and pK A values were compared between agonists at one receptor, then separately between each agonist at the three receptors and then Logτ A and pK A values were compared between assays (for example, mGlu 4 calcium versus mGlu 4 GIRK). All statistical tests were one way ANOVA with a Tukey post-test to compare columns with the exception of between-assay comparisons, which were performed via a student's t-test. Data are comprised of three individual experiments performed in duplicate (Mean ± SD values shown). was measured in the calcium mobilization assay. These data were used to calculate results found in Table 5 and Supplemental Tables 1 and 2 . Data are representative of three individual experiments performed in duplicate.
Supplemental Figure 5 . VU0422288 exhibits efficacy as a PAM for mGlu 4 , mGlu 7 , and mGlu 8 as assessed by calcium mobilization. Increasing concentrations of VU0422288 were applied prior to a full agonist concentration-response curve and the shift of the agonist response was measured in the calcium mobilization assay. These data were used to calculate results found in Table 6 and Supplemental Tables 1 and 2 were calculated for glutamate, L-AP4, and LSP4-2022 at mGlu 4 , mGlu 7 , and mGlu 8 and plotted for the GIRK and calcium pathways. There was a strong correlation noted between assays across all three receptors (linear regression fit, r 2 =0.88). B, C, D. Bias plots for mGlu 4 , mGlu 7
and mGlu 8 reveal that distinct agonists show bias for different receptors. Curves were generated by performing a nonlinear regression across a 150 point range to compare responses between two pathways at equivalent agonist concentrations. Bias factors (ΔΔLog τ/K A ) were calculated using glutamate as the reference agonist and calcium as the reference pathway. These plots correspond to bias factors for L-AP4 at mGlu 4 , mGlu 7 and mGlu 8 of 0.54±0.09, -0.60±0.23, 0.65±0.19 (Mean±S.E.M), respectively. For LSP4-2022 bias factors were 0.91±0.08, -0.62±0.23, 1.02±0.12 (Mean±S.E.M), respectively at mGlu 4 , mGlu 7 and mGlu 8 . Figure S1 . Figure S3 . 
